In a 2013 case study that demonstrated an osteoinductive effect for Ostinol®, a 59-year old woman who was diagnosed with menopause-associated bone problems was taking calcium and vitamin D but was still suffering from a progressive loss of bone mass. Three initial DXA scans of the lower lumbar region of her spine taken at 0, 26, and 53 months provided evidence of progressive bone mineral density loss that is consistent with the advancement of brittle bones. She was administered 200 mg of Ostinol® twice daily for 34 months. The results showed significant improvement in her DEXA scores and by month 8 of Ostinol® use, her bone scans indicated a 10% increase in bone density that was correlated with the cessation of bone loss. After 34 months her bone density score increased 51% from baseline. Furthermore, the L4 vertebrae t score at the initiation of Ostinol® supplementation was -3.0, but this score improved to -0.9 after 34 months of supplementation, thereby indicating normal bone density.
A 2013 clinical trial with 87 participants (55+ years old) who had moderate to severe joint discomfort involved the administration of 150 mg Ostinol® alone, once daily for 12 weeks. The results showed statistically significant improvements. The statistically significant onset of action occurred by day 7. The participants also reported a heightened quality of life in comparison to the controls (placebo group) and none of the participants reported any side effects. The gradual continued to week 12. By week twelve 90% of participants experienced positive results and improved quality of life.
A 2015 clinical trial with 44 participants (55+ years) who had self-reported joint problems were enrolled in this trial. Sixty-eight percent of the participants were diagnosed with joint problems and each of them was administered 150 mg Ostinol® alone, once daily for 4 weeks. The participants showed a 49% improvement in discomfort by week 4, 57% improvement in activity levels by week 4, and 80% improvement in affected joint strength after 4 weeks. Furthermore, none of the participants reported side effect or required any form of rescue treatment.
A 2012 clinical trial with 28 participants who had weak and brittle bones (mean age 61 years) involved the administration of Ostinol® plus glucosamine/chondroitin in a combined tablet daily for 4 weeks. The participants showed a rapid response to the supplementation as early as 7 days after they started taking it. In addition, their positive results continually increased as the supplementation continued. The participants also reported an overall 55% improvement by week 4, with increases in strength and overall activity. None of the participants reported any side effects.